A Review on the Efficacy and Safety of Oral Semaglutide.
Quick Facts
What This Study Found
Oral semaglutide is the first GLP-1 receptor agonist (a gut hormone drug that controls blood sugar and appetite) available as a pill. In the PIONEER trials, it consistently lowered HbA1c (a measure of blood sugar control) and reduced body weight compared to placebo and several other diabetes drugs.
The drug uses an absorption enhancer called SNAC to get through the stomach lining, since peptides normally break down in the gut. Three other GLP-1 drugs (subcutaneous semaglutide, dulaglutide, and liraglutide) already have FDA approval for reducing heart attack and stroke risk in diabetic patients with heart disease.
Oral semaglutide showed signals of heart benefit in early data, but did not yet have an official FDA indication for cardiovascular protection. The SOUL trial was designed to answer that question definitively.
Key Numbers
Oral semaglutide tested at 3, 7, and 14 mg daily; PIONEER trial program; SOUL trial ongoing
How They Did This
This is a narrative review summarizing data from the PIONEER trial program, which tested oral semaglutide at various doses against placebo and active comparators in patients with type 2 diabetes. The review covers efficacy for blood sugar control, weight loss, and cardiovascular outcomes.
Why This Research Matters
Most GLP-1 drugs require injections, which many patients avoid. Having a pill option removes that barrier and could lead to earlier treatment. If oral semaglutide also proves to protect the heart, it would be the first oral GLP-1 with that benefit.
What This Study Doesn't Tell Us
This is a review, not an original study. It summarizes existing trial data without new analysis. The cardiovascular benefit question was still unanswered at publication time. The review does not deeply compare oral semaglutide to newer agents like tirzepatide.
Trust & Context
- Original Title:
- A Review on the Efficacy and Safety of Oral Semaglutide.
- Published In:
- Drugs in R&D, 21(2), 133-148 (2021)
- Authors:
- Niman, Stephanie, Hardy, Jennifer, Goldfaden, Rebecca F, Reid, Jessica, Sheikh-Ali, Mae, Sutton, David, Choksi, Rushab
- Database ID:
- RPEP-05647
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05647APA
Niman, Stephanie; Hardy, Jennifer; Goldfaden, Rebecca F; Reid, Jessica; Sheikh-Ali, Mae; Sutton, David; Choksi, Rushab. (2021). A Review on the Efficacy and Safety of Oral Semaglutide.. Drugs in R&D, 21(2), 133-148. https://doi.org/10.1007/s40268-021-00341-8
MLA
Niman, Stephanie, et al. "A Review on the Efficacy and Safety of Oral Semaglutide.." Drugs in R&D, 2021. https://doi.org/10.1007/s40268-021-00341-8
RethinkPeptides
RethinkPeptides Research Database. "A Review on the Efficacy and Safety of Oral Semaglutide." RPEP-05647. Retrieved from https://rethinkpeptides.com/research/niman-2021-a-review-on-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.